PubMed · 14934326
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
M BERLAND. 1951. [On BCG].. https://pubmed.ncbi.nlm.nih.gov/14934326/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Japanese bacillus Calmette-Guerin (BCG) vaccine preparation contains two types of variant strains, Type I, which has a 22-base-pair deletion in the RD16 region, and Type II, which has an identical sequence to those of other BCG strains. In this study, we established a method to quantify the percentage of variant strain Type II contained in freeze-dried BCG product with real-time PCR. With this method we examined the master seed lot Tokyo 172, two secondary seed lots, Tokyo 172-1 and Tokyo 172-2, which were produced from Tokyo 172, and four commercial lots produced form Tokyo 172-1. Tokyo 172, Tokyo 172-1, and Tokyo 172-2 contained 55.1%, 19.5%, and 3.6% of Type II variant strain, respectively. Commercial lots contained 1.5%, 4.5%, 7.4%, and 4.3% of Type II variant strain, respectively. These results indicated that the two variant strains contained in the master seed lot continued to coexist in subsequently produced lots with a decrease in population of variant strain Type II. This method would be useful for quality control of commercial Japanese BCG vaccine preparations.
Mounting evidence points to CD8+ T cells playing an important role in protective immunity against Mycobacterium tuberculosis. The only available vaccine against tuberculosis, bacillus Calmette Guérin (BCG), has traditionally been viewed not to induce these cells optimally. In this study, we show that vaccination of human newborns with BCG does indeed induce a specific CD8+ T cell response. These cells degranulated or secreted IFN-gamma, but not both, when infant blood was incubated with BCG. This stimulation also resulted in proliferation and up-regulation of cytotoxic molecules. Overall, the specific CD8+ T cell response was quantitatively smaller than the BCG-induced CD4+ T cell response. Incubation of whole blood with M. tuberculosis also caused CD8+ T cell IFN-gamma expression. We conclude that BCG induces a robust CD8+ T cell response, which may contribute to vaccination-induced protection against tuberculosis.
The aim of this study was to determine the tuberculin skin test (TST) response to three different BCG modalities [0.1 ml Tokyo (n=104), 0.05 ml Pasteur-Mérieux (n=137) and 0.1 ml Pasteur-Mérieux (n=100)] in a cohort of healthy newborns 5 months after vaccination at birth in Santiago, Chile. Among the 341 infants, 91.2% had a response to TST, and the mean+/-SD TST reaction size was significantly larger in infants receiving the Tokyo strain than in those receiving the 0.05 ml or 0.1 ml Pasteur-Mérieux strains (4.4+/-2.0, 3.5+/-1.3 and 3.1+/-1.4 mm, respectively; P<0.0001). The mean+/-SD of the BCG scar size was significantly lower in infants vaccinated with the Tokyo strain than in those vaccinated with the 0.1 ml Pasteur-Mérieux strain (3.9+/-1.2 vs. 4.3+/-1.1 mm; P=0.03) and no significant difference was found between infants receiving the Tokyo strain and the 0.05 ml Pasteur-Mérieux strain. However, the differences in TST size induced by diverse BCG vaccination modalities may not reflect the quality of the immunologically induced response in terms of TB protection.